Azopharma has established relationships with iQ Synthesis and Cyanta Drug Development, expanding its Product Development Group.

Phil Meeks, chief executive officer of the Azopharma Product Development Group of companies, said, “These two additions, combined with our four current companies, will round out our service offering portfolio and enhance our position as a major resource in the global contract product development arena. We are now poised to capitalize on the emerging trends transforming the pharmaceutical industry. Our entire network now consists of a family of six companies with capabilities ranging from preclinical to manufacturing. Working either individually or in conjunction, these companies offer tailored choices to the pharmaceutical and medical device industries of North America, Europe, and Asia.”

This group of companies includes: Azopharma Contract Services, offering product development and CTM manufacturing; IQ Synthesis, offering synthetic chemistry services from discovery to clinical materials; ApiCross Drug Delivery for insoluble compounds; Aniclin Preclinical Services in support of early product development, Cyanta Drug Development, offering analytical chemistry services from development to QC testing, and AvivoClin Clinical Services, offering human clinical pharmacology services for Phase I trials.